https://www.selleckchem.com/pr....oducts/vanzacaftor.h
hould be of particular importance in the context of patients without access to third-generation targeted agents. Further studies are warranted to ascertain this effect. Among a selected population at high risk for developing BM, PCI significantly decreased CBM in addition to increasing progression-free survival and OS. To our knowledge, this is the first study to evaluate PCI in epidermal growth factor receptor mutations, anaplastic lymphoma kinase rearrangements, or elevated carcinoembryonic antigen levels in patients with NSCLC, s
Gefällt mir
Kommentar
Teilen
